cydy

Healthcare

CytoDyn (OTC: CYDY) Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing Purposes

July 29, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Executes Exclusive Worldwide Licensing Agreement with IncellDX for PA-14 and PRO 140 for Diagnostic Testing Purposes

Agreement represents a revenue opportunity as a diagnostic test for receptor occupancy and the existence of CCR5 on cancer tissue and in HIV VANCOUVER, Washington, Jul 26, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]

Healthcare

CytoDyn (OTC: CYDY) Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA

July 29, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA

VANCOUVER, Washington, Jul 25, 2019– – FDA face-to-face meeting granted to discuss pivotal monotherapy trial – Conference call for investors and media on Tuesday, July 30, 2019 at 4:00 p.m. ET with introduction to Dr. […]

Healthcare

CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

July 1, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Anticipates Revenue Commencing in August 2019 from Use of PA-14 and/or PRO 140 in Diagnostic Test

CytoDyn Signs Non-binding Agreement for Diagnostic Licenseand Supply Agreement with IncellDX for PA-14 and/or PRO 140 (non-commercial grade) Collaboration represents an immediate revenue opportunity as a diagnostic test for receptor occupancy and the existence of […]

Healthcare

CytoDyn (OTC: CYDY) Submits 510(k) Pre-Submission Application to U.S. FDA for ProstaGene(TM) Prognostic Test

June 20, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Submits 510(k) Pre-Submission Application to U.S. FDA for ProstaGene(TM) Prognostic Test

Dr. Richard Pestell, who leads CytoDyn’s cancer, NASH and GvHD programs, recently named to The Order of Australia, established by Queen Elizabeth II VANCOUVER, Washington, June 19, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the […]

Healthcare

CytoDyn (OTC: CYDY) Signs Groundbreaking Memorandum of Understanding with Thai Red Cross AIDS Research Centre to Study Pre-Exposure Prophylaxis Use of Leronlimab (PRO 140) in People at High Risk of Acquiring HIV

June 17, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Signs Groundbreaking Memorandum of Understanding with Thai Red Cross AIDS Research Centre to Study Pre-Exposure Prophylaxis Use of Leronlimab (PRO 140) in People at High Risk of Acquiring HIV

VANCOUVER, Washington, June 17, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today a Memorandum […]

Healthcare

CytoDyn Raises over $12 Million in New Capital from Private and Public Warrant Offers in the Last Five Weeks with Minimum Dilution

June 17, 2019 admin Comments Off on CytoDyn Raises over $12 Million in New Capital from Private and Public Warrant Offers in the Last Five Weeks with Minimum Dilution

VANCOUVER, Washington, June 14, 2019  — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications announced today that it […]

Newsmakers

ASM Microbe 2019 Conference Grants Both Poster and Oral Presentations to CytoDyn (OTC: CYDY) for its Pivotal Study of Leronlimab (PRO 140) which Demonstrated Superior Efficacy and Safety in Heavily Treatment-Experienced HIV Patients

April 5, 2019 admin Comments Off on ASM Microbe 2019 Conference Grants Both Poster and Oral Presentations to CytoDyn (OTC: CYDY) for its Pivotal Study of Leronlimab (PRO 140) which Demonstrated Superior Efficacy and Safety in Heavily Treatment-Experienced HIV Patients

VANCOUVER, Washington, Apr 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that […]

Healthcare

CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

March 21, 2019 admin Comments Off on CytoDyn (OTC: CYDY) Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

FDA Previously Granted Rolling Review for BLA VANCOUVER, Washington, Mar 18, 2019 – CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential […]

Healthcare

CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

March 12, 2019 admin Comments Off on CytoDyn (OTC: CYDY)Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

VANCOUVER, Washington, March 11, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that leronlimab (PRO 140), […]

Healthcare

FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

March 7, 2019 admin Comments Off on FDA Grants Rolling Review for CytoDyn’s (OTC: CYDY) Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 — CytoDyn Inc. (otc.qb:CYDY), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed […]

Healthcare

CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

February 28, 2019 admin Comments Off on CytoDyn (OTC: CYDY) to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

VANCOUVER, Washington, Feb. 27, 2019 — CytoDyn Inc. (OTC.QB: CYDY), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab […]